Overdiagnosis and overtreatment of breast cancer -: Progression of ductal carcinoma in situ:: the pathological perspective

被引：49

作者：

Jones, JL ^{[1
]}

机构：

[1] Queen Marys Sch Med & Dent, Tumour Biol Lab, Inst Canc, London, England

来源：

BREAST CANCER RESEARCH | 2006年 / 8卷 / 02期

关键词：

D O I：

10.1186/bcr1397

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ductal carcinoma in situ (DCIS) is encountered much more frequently in the screening population compared to the symptomatic setting. The behaviour of DCIS is highly variable and this presents difficulties in choosing appropriate treatment strategies for individual cases. This review discusses the current data on the frequency and rate of progression of DCIS, the value and limitations of clinicopathological and biological variables in predicting disease behaviour and suggests strategies to develop more robust means of predicting progression of DCIS.

引用

页数：4

共 28 条

[1]

Adams M, 2002, CANCER RES, V62, P3289

[2] Molecular characterization of the tumor microenvironment in breast cancer [J].

Allinen, M ;

Beroukhim, R ;

Cai, L ;

Brennan, C ;

Lahti-Domenici, J ;

Huang, HY ;

Porter, D ;

Hu, M ;

Chin, L ;

Richardson, A ;

Schnitt, S ;

Sellers, WR ;

Polyak, K .

CANCER CELL, 2004, 6 (01) :17-32

[3] Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications:: A comparative study with long follow-up [J].

Badve, S ;

A'Hern, RP ;

Ward, AM ;

Millis, RR ;

Pinder, SE ;

Ellis, IO ;

Gusterson, BA ;

Sloane, JP .

HUMAN PATHOLOGY, 1998, 29 (09) :915-923

[4] Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast [J].

Barnes, NLP ;

Khavari, S ;

Boland, GP ;

Cramer, A ;

Knox, WF ;

Bundred, NJ .

CLINICAL CANCER RESEARCH, 2005, 11 (06) :2163-2168

[5] INTRADUCTAL CARCINOMA - LONG-TERM FOLLOW-UP AFTER TREATMENT BY BIOPSY ALONE [J].

BETSILL, WL ;

ROSEN, PP ;

LIEBERMAN, PH ;

ROBBINS, GF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (18) :1863-1867

[6] Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].

Bijker, N ;

Peterse, JL ;

Duchateau, L ;

Julien, JP ;

Fentiman, IS ;

Duval, C ;

Di Palma, S ;

Simony-Lafontaine, J ;

de Mascarel, I ;

van de Vijver, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271

[7] Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy - Results from the Nurses' Health Study [J].

Collins, LC ;

Tamimi, RM ;

Baer, HJ ;

Connolly, JL ;

Colditz, GA ;

Schnitt, SJ .

CANCER, 2005, 103 (09) :1778-1784

[8] The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast - A study of a large cohort of patients treated with surgery alone [J].

Cornfield, DB ;

Palazzo, JP ;

Schwartz, GF ;

Goonewardene, SA ;

Kovatich, AJ ;

Chervoneva, I ;

Hyslop, T ;

Schwarting, R .

CANCER, 2004, 100 (11) :2317-2327

[9] p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast [J].

Done, SJ ;

Eskandarian, S ;

Bull, S ;

Redston, M ;

Andrulis, IL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :700-704

[10] Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].

Ernster, VL ;

Barclay, J ;

Kerlikowske, K ;

Wilkie, H ;

Ballard-Barbash, R .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958

← 1 2 3 →